| Dear Voornaam,
Welcome to your weekly Cancer Research UK Research Update email.
High inflation and currency volatility are continuing to have an impact on researchers, in terms of both the cost of living and the cost of doing research.
This week, we’ve reviewed our support and we’re bringing in increases in two areas – for students and for newly awarded grants.
To address the worry and hardship we know many students have been facing, we’re increasing stipends by £2,000 to £21,000 for students outside London and £23,000 for those inside London. This is for all students in years 1-4 of their PhD, who receive a Cancer Research UK stipend in our institutes, centres and on grants and will apply from 1 October 2022.
We’re also increasing the indexation rate for new response mode awards made by our funding committees in 2022/23 and 2023/24, and we’ll be in touch directly with grant recipients to confirm the adjustments we will be making.
This obviously won’t cover the full increases that people will see, but with no new money available in our research budgets, we’ve sought to target what we can afford to the most vulnerable while we continue to review the support we offer in other areas. We’ll be in touch with grantees and institutions to confirm how we’ll provide the additional funds to cover the increase.
Kind regards
Iain
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK
|
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
NEW IN NATURE GENETICS: ION CHANNEL NALCN REGULATES METASTASIS AND NON-MALIGNANT CELL DISSEMINATION Metastasis isn’t an abnormal process limited to cancer – this is the surprising finding published in Nature Genetics last week (29 September).
Eric Rahrmann, Richard Gilbertson and colleagues found that deletion of the ion channel NALCN from gastric, intestinal or pancreatic adenocarcinomas in mice did not alter tumour incidence, but markedly increased metastases.
Blocking NALCN in mice without cancer caused shedding of epithelial cells. These were then trafficked to distant organs, showing that NALCN regulates cell shedding from solid tissues independent of cancer status.
These findings suggest that cancers exploit a normal cell tissue shedding and repair process to generate metastases, and pave the way for new antimetastatic therapy approaches targeting NALCN channels. |
|
|---|
|
|---|
|
|
DOREEN CANTRELL AND GERARD EVAN APPOINTED AS TRUSTEES Doreen and Gerard both have longstanding associations with Cancer Research UK, and their extensive expertise will be crucial in helping shape our strategic direction over the coming years.
We're grateful to have them on board and wish them all the best for their new roles. |
|
|---|
|
|---|
|
|
NEW TARGETED LUNG CANCER SCREENING PROGRAMME ON THE HORIZON The UK National Screening Committee has recommended introducing a targeted lung cancer screening programme across the UK for people with a history of smoking and at high risk – a positive, long-awaited step towards applying risk-stratified screening approaches to help detect lung cancer early.
Lung cancer is the most common cause of cancer death in the UK, with 35,000 deaths each year. Despite research redefining our understanding of the disease and setting new standards of care, improving outcomes in lung cancer remains a huge challenge.
Such a screening programme would benefit the NHS by looking for lung cancer in a population at greatest risk, direct care to those who need it most, and aim to detect and diagnose lung cancer at a stage when it can be curatively treated, even when someone may not have any symptoms. |
|
|---|
|
|---|
|
|
EXPLORING WHAT’S BEHIND THE LATE EFFECTS OF MEDULLOBLASTOMA TREATMENT In case you missed it, as part of Childhood Cancer Awareness Month we spoke to Dr Debbie Hicks, Fellow of Molecular Cancer Survivorship at Newcastle University, about what is being done to understand and minimise the impact of long-term side effects for children and young people with medulloblastoma.
Medulloblastoma is the most common malignant brain tumour in children and young people, and even though more are surviving, treatment can have a late-effect profile and greatly impact their quality of life. Medulloblastoma survivors are also at higher risk of second cancers.
Debbie’s research aims to better understand the complexity and biological underpinnings of medulloblastoma, its treatment and the late-effect profile, and derive novel biomarker-driven, risk-stratification models that work towards the application of precision therapies. |
|
|---|
|
|---|
|
|
JOIN US AT THE HDR UK SCIENTIFIC CONFERENCE: DATA FOR GLOBAL HEALTH AND SOCIETY We’re partnering with Health Data Research UK at their annual Scientific Conference on 14 December.
This is a free, one-day, hybrid event in Birmingham featuring talks, panel discussions, awards for excellence in health data science, and opportunities to exchange ideas with leading national and international colleagues, patients and the public across the health data research community.
Follow along with #HDRUKSciConf and stay tuned for more information, including how you can connect directly with our Research Data Strategy team at the event. |
|
|---|
| LOOKING TO PUBLISH YOUR RESEARCH? DON’T FORGET TO KEEP US IN THE LOOP Are you preparing a Cancer Research UK-funded research paper for publication? If so, we'd love to hear about it.
You can let us know about pending publications via our manuscript notification form. All information will be treated confidentially and won’t be used without consulting you first.
Knowing in advance about upcoming publications helps us plan our communications and means we can better talk to our supporters about the amazing work that their donations help fund. |
|
|---|
|
|---|
|
|
| | | London, UK 10 October 2022 |
|
|---|
|
|---|
| | | Amsterdam, Netherlands 14 October 2022 |
|
|---|
|
|---|
| | | Portland, Oregon, USA 18 October 2022 |
|
|---|
|
|---|
| | | Manchester, UK 15 November 2022 |
|
|---|
|
|---|
| | | East Sussex, UK 04 December 2022 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
